Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Rising High: Exclusive talk with biotech company Tryp Therapeutics » 11:59
05/19/22
05/19
11:59
05/19/22
11:59
GDNSF

Goodness Growth

$1.42 /

-0.05 (-3.40%)

, ZYNE

Zynerba

/

+

, TCNNF

Trulieve Cannabis

$14.37 /

-0.135 (-0.93%)

, TLRY

Tilray

$4.94 /

+0.15 (+3.13%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$11.67 /

-0.52 (-4.27%)

, CANN

General Cannabis

/

+

, CRON

Cronos Group

$3.48 /

+0.155 (+4.66%)

, CGC

Canopy Growth

$5.89 /

+0.3 (+5.37%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$3.08 /

+0.175 (+6.02%)

, RLMD

Relmada Therapeutics

$21.30 /

-0.3 (-1.39%)

, CMPS

Compass Pathways

$8.59 /

+0.36 (+4.37%)

, ATAI

Atai Life Sciences

$4.07 /

+0.125 (+3.17%)

, TRYPF

Tryp Therapeutics

/

+

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TRYPF Tryp Therapeutics
/

+

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
ZYNE Zynerba
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
TLRY Tilray
$4.94 /

+0.15 (+3.13%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
CANN General Cannabis
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

05/20/22 Alliance Global Partners
Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
TRYPF Tryp Therapeutics
/

+

08/26/21 Ladenburg
Tryp Therapeutics initiated with a Buy at Ladenburg
ZYNE Zynerba
/

+

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

CVSI CV Sciences
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

  • 09
    Dec
  • 18
    Jun
GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

Over a week ago
On The Fly
Rising High: Exclusive talk with cannabis REIT NewLake Capital » 11:42
05/12/22
05/12
11:42
05/12/22
11:42
RLMD

Relmada Therapeutics

$18.51 /

-0.07 (-0.38%)

, CMPS

Compass Pathways

$7.03 /

+0.23 (+3.38%)

, ATAI

Atai Life Sciences

$3.32 /

+0.19 (+6.07%)

, ZYNE

Zynerba

/

+

, TCNNF

Trulieve Cannabis

$13.60 /

-0.43 (-3.06%)

, TLRY

Tilray

$4.43 /

+0.37 (+9.11%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$11.76 /

+0.05 (+0.43%)

, GDNSF

Goodness Growth

$1.49 /

-0.032 (-2.11%)

, CANN

General Cannabis

/

+

, CRON

Cronos Group

$3.14 /

+0.15 (+5.02%)

, CGC

Canopy Growth

$5.47 /

+0.49 (+9.84%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$2.47 /

+0.175 (+7.64%)

, NLCP

NewLake Capital Partners

$19.88 /

+0.03 (+0.15%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$4.43 /

+0.37 (+9.11%)

TCNNF Trulieve Cannabis
$13.60 /

-0.43 (-3.06%)

RLMD Relmada Therapeutics
$18.51 /

-0.07 (-0.38%)

NLCP NewLake Capital Partners
$19.88 /

+0.03 (+0.15%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.76 /

+0.05 (+0.43%)

GDNSF Goodness Growth
$1.49 /

-0.032 (-2.11%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.14 /

+0.15 (+5.02%)

CMPS Compass Pathways
$7.03 /

+0.23 (+3.38%)

CGC Canopy Growth
$5.47 /

+0.49 (+9.84%)

ATAI Atai Life Sciences
$3.32 /

+0.19 (+6.07%)

ACB Aurora Cannabis
$2.47 /

+0.175 (+7.64%)

RLMD Relmada Therapeutics
$18.51 /

-0.07 (-0.38%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
CMPS Compass Pathways
$7.03 /

+0.23 (+3.38%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
ATAI Atai Life Sciences
$3.32 /

+0.19 (+6.07%)

04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
ZYNE Zynerba
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
TCNNF Trulieve Cannabis
$13.60 /

-0.43 (-3.06%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
TLRY Tilray
$4.43 /

+0.37 (+9.11%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.76 /

+0.05 (+0.43%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
GDNSF Goodness Growth
$1.49 /

-0.032 (-2.11%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
CANN General Cannabis
/

+

CRON Cronos Group
$3.14 /

+0.15 (+5.02%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CGC Canopy Growth
$5.47 /

+0.49 (+9.84%)

04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
03/01/22 Barclays
Canopy Growth price target lowered to $9 from $14 at Barclays
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$2.47 /

+0.175 (+7.64%)

05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
02/03/22 CIBC
Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
NLCP NewLake Capital Partners
$19.88 /

+0.03 (+0.15%)

03/21/22 Ladenburg
NewLake Capital price target lowered to $39.50 from $44 at Ladenburg
09/08/21 Compass Point
NewLake Capital Partners initiated with a Buy at Compass Point
09/07/21 Ladenburg
NewLake Capital Partners initiated with a Buy at Ladenburg
ZYNE Zynerba
/

+

TLRY Tilray
$4.43 /

+0.37 (+9.11%)

TCNNF Trulieve Cannabis
$13.60 /

-0.43 (-3.06%)

RLMD Relmada Therapeutics
$18.51 /

-0.07 (-0.38%)

NLCP NewLake Capital Partners
$19.88 /

+0.03 (+0.15%)

GTBIF Green Thumb Industries
$11.76 /

+0.05 (+0.43%)

CVSI CV Sciences
/

+

CRON Cronos Group
$3.14 /

+0.15 (+5.02%)

CMPS Compass Pathways
$7.03 /

+0.23 (+3.38%)

CGC Canopy Growth
$5.47 /

+0.49 (+9.84%)

ATAI Atai Life Sciences
$3.32 /

+0.19 (+6.07%)

ACB Aurora Cannabis
$2.47 /

+0.175 (+7.64%)

  • 09
    Dec
  • 18
    Jun
ZYNE Zynerba
/

+

RLMD Relmada Therapeutics
$18.51 /

-0.07 (-0.38%)

NLCP NewLake Capital Partners
$19.88 /

+0.03 (+0.15%)

CRON Cronos Group
$3.14 /

+0.15 (+5.02%)

CGC Canopy Growth
$5.47 /

+0.49 (+9.84%)

TLRY Tilray
$4.43 /

+0.37 (+9.11%)

CRON Cronos Group
$3.14 /

+0.15 (+5.02%)

CGC Canopy Growth
$5.47 /

+0.49 (+9.84%)

ATAI Atai Life Sciences
$3.32 /

+0.19 (+6.07%)

ACB Aurora Cannabis
$2.47 /

+0.175 (+7.64%)

Earnings
Compass Pathways reports Q1 EPS (50c), consensus (67c) » 07:10
05/10/22
05/10
07:10
05/10/22
07:10
CMPS

Compass Pathways

$7.37 /

-0.9 (-10.88%)

Cash and cash equivalents…

Cash and cash equivalents were $243.7 million as of 31 March 2022 compared with $273.2 million as of December 31, 2021.

ShowHide Related Items >><<
CMPS Compass Pathways
$7.37 /

-0.9 (-10.88%)

CMPS Compass Pathways
$7.37 /

-0.9 (-10.88%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
CMPS Compass Pathways
$7.37 /

-0.9 (-10.88%)

CMPS Compass Pathways
$7.37 /

-0.9 (-10.88%)

Hot Stocks
Compass Pathways to fund study of COMP360 psilocybin in autistic adults » 07:16
05/09/22
05/09
07:16
05/09/22
07:16
CMPS

Compass Pathways

$8.28 /

-0.58 (-6.55%)

COMPASS Pathways…

COMPASS Pathways announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults. The double-blind, randomized, placebo-controlled study will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin. It is an investigator-initiated exploratory study that will take place at the Institute of Psychiatry, Psychology & Neuroscience at King's College London. The study is co-sponsored by King's IoPPN and South London and Maudsley NHS Foundation Trust. It will enroll 70 adult participants, including 40 autistic people and 30 non-autistic people. The study is led by Professor Grainne McAlonan, Professor of Translational Neuroscience at King's IoPPN, and conducted by Tobias Whelan, PhD student at King's and Research Scientist at COMPASS Pathways.

ShowHide Related Items >><<
CMPS Compass Pathways
$8.28 /

-0.58 (-6.55%)

CMPS Compass Pathways
$8.28 /

-0.58 (-6.55%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
CMPS Compass Pathways
$8.28 /

-0.58 (-6.55%)

CMPS Compass Pathways
$8.28 /

-0.58 (-6.55%)

CMPS Compass Pathways
$8.28 /

-0.58 (-6.55%)

On The Fly
Here's What You Missed in Cannabis, Psychedelics This Week » 11:42
05/05/22
05/05
11:42
05/05/22
11:42
GTBIF

Green Thumb Industries

$12.82 /

-0.22 (-1.69%)

, ETRGF

Entourage Health

/

+

, FFLWF

Fire & Flower Holdings

$2.66 /

+0.09 (+3.50%)

, CMPS

Compass Pathways

$9.11 /

-0.39 (-4.11%)

, WSNAF

Wesana Health

/

+

, TLRY

Tilray

$4.96 /

-0.35 (-6.59%)

, ACB

Aurora Cannabis

$2.95 /

-0.25 (-7.82%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$6.25 /

-0.45 (-6.72%)

, CRON

Cronos Group

$3.07 /

-0.175 (-5.39%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.65 /

-0.02 (-1.20%)

, IGC

India Globalization Capital

/

+

, TCNNF

Trulieve Cannabis

$13.75 /

+0.01 (+0.07%)

, ZYNE

Zynerba

$1.35 /

-0.05 (-3.57%)

, RLMD

Relmada Therapeutics

$23.27 /

-0.96 (-3.96%)

, ATAI

Atai Life Sciences

$4.04 /

-0.35 (-7.97%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.35 /

-0.05 (-3.57%)

WSNAF Wesana Health
/

+

TLRY Tilray
$4.96 /

-0.35 (-6.59%)

TCNNF Trulieve Cannabis
$13.75 /

+0.01 (+0.07%)

RLMD Relmada Therapeutics
$23.27 /

-0.96 (-3.96%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$12.82 /

-0.22 (-1.69%)

GDNSF Goodness Growth
$1.65 /

-0.02 (-1.20%)

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.07 /

-0.175 (-5.39%)

CMPS Compass Pathways
$9.11 /

-0.39 (-4.11%)

CGC Canopy Growth
$6.25 /

-0.45 (-6.72%)

ATAI Atai Life Sciences
$4.04 /

-0.35 (-7.97%)

ACB Aurora Cannabis
$2.95 /

-0.25 (-7.82%)

GTBIF Green Thumb Industries
$12.82 /

-0.22 (-1.69%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
ETRGF Entourage Health
/

+

11/18/21 Canaccord
Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
11/17/21 Canaccord
Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
FFLWF Fire & Flower Holdings
$2.66 /

+0.09 (+3.50%)

04/28/22 Stifel
Fire & Flower Holdings price target lowered to C$8.50 from C$12 at Stifel
12/15/21 Stifel
Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel
11/23/21 Cantor Fitzgerald
Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald
11/22/21 Cantor Fitzgerald
Fire & Flower initiated with an Overweight at Cantor Fitzgerald
CMPS Compass Pathways
$9.11 /

-0.39 (-4.11%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
WSNAF Wesana Health
/

+

04/01/22 Stifel
Wesana Health initiated with a Speculative Buy at Stifel
TLRY Tilray
$4.96 /

-0.35 (-6.59%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
ACB Aurora Cannabis
$2.95 /

-0.25 (-7.82%)

02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
02/03/22 CIBC
Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
11/11/21 Canaccord
Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
CVSI CV Sciences
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CGC Canopy Growth
$6.25 /

-0.45 (-6.72%)

04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
03/01/22 Barclays
Canopy Growth price target lowered to $9 from $14 at Barclays
CRON Cronos Group
$3.07 /

-0.175 (-5.39%)

03/22/22 Barclays
Cronos Group upgraded to Equal Weight from Underweight at Barclays
03/21/22 Stifel
Stifel takes neutral overall view of Cronos' CEO transition
03/07/22 Piper Sandler
Cronos Group price target lowered to $3 from $4 at Piper Sandler
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.65 /

-0.02 (-1.20%)

02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
IGC India Globalization Capital
/

+

TCNNF Trulieve Cannabis
$13.75 /

+0.01 (+0.07%)

03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
03/29/22 Cantor Fitzgerald
Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald
ZYNE Zynerba
$1.35 /

-0.05 (-3.57%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$23.27 /

-0.96 (-3.96%)

12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
07/28/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
ATAI Atai Life Sciences
$4.04 /

-0.35 (-7.97%)

04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
ZYNE Zynerba
$1.35 /

-0.05 (-3.57%)

TLRY Tilray
$4.96 /

-0.35 (-6.59%)

RLMD Relmada Therapeutics
$23.27 /

-0.96 (-3.96%)

GTBIF Green Thumb Industries
$12.82 /

-0.22 (-1.69%)

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$3.07 /

-0.175 (-5.39%)

CMPS Compass Pathways
$9.11 /

-0.39 (-4.11%)

CGC Canopy Growth
$6.25 /

-0.45 (-6.72%)

ATAI Atai Life Sciences
$4.04 /

-0.35 (-7.97%)

ACB Aurora Cannabis
$2.95 /

-0.25 (-7.82%)

  • 09
    Dec
  • 18
    Jun
GTBIF Green Thumb Industries
$12.82 /

-0.22 (-1.69%)

WSNAF Wesana Health
/

+

GTBIF Green Thumb Industries
$12.82 /

-0.22 (-1.69%)

FFLWF Fire & Flower Holdings
$2.66 /

+0.09 (+3.50%)

TLRY Tilray
$4.96 /

-0.35 (-6.59%)

CRON Cronos Group
$3.07 /

-0.175 (-5.39%)

CMPS Compass Pathways
$9.11 /

-0.39 (-4.11%)

CGC Canopy Growth
$6.25 /

-0.45 (-6.72%)

ATAI Atai Life Sciences
$4.04 /

-0.35 (-7.97%)

ACB Aurora Cannabis
$2.95 /

-0.25 (-7.82%)

Hot Stocks
Compass Pathways announces data on COMP360 psilocybin therapy » 07:23
05/03/22
05/03
07:23
05/03/22
07:23
CMPS

Compass Pathways

$9.79 /

+0.72 (+7.94%)

COMPASS Pathways…

COMPASS Pathways announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from two investigator-initiated studies.The first study looked at the safety and efficacy of COMP360 psilocybin therapy in patients with severe treatment-resistant depression, with a single 25mg dose, and was run by Dr Scott Aaronson at Sheppard Pratt, Baltimore. The researchers found that 58.3% of the participants had maintained response criteria, for the Montgomery-Asberg Depression Rating Scale, MADRS, at 12 weeks after COMP360 psilocybin administration, and a quarter had maintained remission. There was no increase in the suicidality score based on the MADRS, and no serious adverse events were reported throughout the study. The second study investigated the safety, efficacy, and tolerability of COMP360 psilocybin therapy in patients with anorexia nervosa, with a single 25mg dose, and was conducted by Dr Walter Kaye at the University of California San Diego School of Medicine. 30% of participants experienced clinically significant reductions in eating disorder psychopathology at the 1-month follow up, and 40% experienced clinically significant reductions at the 3-month follow-up. Participants demonstrated statistically significant reductions in shape concerns at the 1-month follow-up, and statistically significant reductions in eating concerns at the 3-month follow-up. Changes in weight concerns were approaching statistical significance. COMP360 psilocybin therapy was well-tolerated and 90% of participants found the experience to be meaningful and therapeutic. No serious adverse events were reported.

ShowHide Related Items >><<
CMPS Compass Pathways
$9.79 /

+0.72 (+7.94%)

CMPS Compass Pathways
$9.79 /

+0.72 (+7.94%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
CMPS Compass Pathways
$9.79 /

+0.72 (+7.94%)

CMPS Compass Pathways
$9.79 /

+0.72 (+7.94%)

CMPS Compass Pathways
$9.79 /

+0.72 (+7.94%)

On The Fly
Here's What You Missed in Cannabis This Week » 10:51
04/28/22
04/28
10:51
04/28/22
10:51
TCNNF

Trulieve Cannabis

$15.08 /

-0.91 (-5.69%)

, CLVR

Clever Leaves

$1.41 /

-0.055 (-3.75%)

, CGC

Canopy Growth

$5.10 /

-0.125 (-2.39%)

, MMNFF

MedMen

/

+

, SKYE

Skye Bioscience

/

+

, ACB

Aurora Cannabis

$2.82 /

-0.11 (-3.75%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CRON

Cronos Group

$2.88 /

-0.05 (-1.71%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.62 /

-0.09 (-5.26%)

, GTBIF

Green Thumb Industries

$14.46 /

-1.18 (-7.54%)

, IGC

India Globalization Capital

/

+

, TLRY

Tilray

$4.86 /

-0.15 (-3.00%)

, ZYNE

Zynerba

$1.34 /

-0.045 (-3.26%)

, ATAI

Atai Life Sciences

$4.40 /

-0.195 (-4.24%)

, CMPS

Compass Pathways

$9.55 /

-0.655 (-6.42%)

, RLMD

Relmada Therapeutics

$23.38 /

-0.91 (-3.75%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.34 /

-0.045 (-3.26%)

TLRY Tilray
$4.86 /

-0.15 (-3.00%)

TCNNF Trulieve Cannabis
$15.08 /

-0.91 (-5.69%)

SKYE Skye Bioscience
/

+

RLMD Relmada Therapeutics
$23.38 /

-0.91 (-3.75%)

MMNFF MedMen
/

+

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$14.46 /

-1.18 (-7.54%)

GDNSF Goodness Growth
$1.62 /

-0.09 (-5.26%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$2.88 /

-0.05 (-1.71%)

CMPS Compass Pathways
$9.55 /

-0.655 (-6.42%)

CLVR Clever Leaves
$1.41 /

-0.055 (-3.75%)

CGC Canopy Growth
$5.10 /

-0.125 (-2.39%)

ATAI Atai Life Sciences
$4.40 /

-0.195 (-4.24%)

ACB Aurora Cannabis
$2.82 /

-0.11 (-3.75%)

TCNNF Trulieve Cannabis
$15.08 /

-0.91 (-5.69%)

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
03/29/22 Cantor Fitzgerald
Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald
CLVR Clever Leaves
$1.41 /

-0.055 (-3.75%)

03/28/22 Cowen
Clever Leaves price target lowered to $4 from $6 at Cowen
02/10/22 Canaccord
Clever Leaves price target lowered to $7 from $10 at Canaccord
12/23/21 Canaccord
Clever Leaves price target lowered to $10 from $12 at Canaccord
11/12/21 Cowen
Clever Leaves price target lowered to $6 from $11 at Cowen
CGC Canopy Growth
$5.10 /

-0.125 (-2.39%)

04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
03/01/22 Barclays
Canopy Growth price target lowered to $9 from $14 at Barclays
MMNFF MedMen
/

+

01/04/22 Needham
Ascend Wellness price target lowered to $11 from $13 at Needham
11/11/21 Canaccord
MedMen price target lowered to C$0.35 from C$0.40 at Canaccord
09/24/21 Canaccord
MedMen upgraded to Hold from Sell at Canaccord
08/18/21 BMO Capital
Tilray announces initial U.S. cannabis pathway via MedMen, says BMO Capital
SKYE Skye Bioscience
/

+

ACB Aurora Cannabis
$2.82 /

-0.11 (-3.75%)

02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
02/03/22 CIBC
Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
11/11/21 Canaccord
Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
CVSI CV Sciences
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CRON Cronos Group
$2.88 /

-0.05 (-1.71%)

03/22/22 Barclays
Cronos Group upgraded to Equal Weight from Underweight at Barclays
03/21/22 Stifel
Stifel takes neutral overall view of Cronos' CEO transition
03/07/22 Piper Sandler
Cronos Group price target lowered to $3 from $4 at Piper Sandler
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.62 /

-0.09 (-5.26%)

02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$14.46 /

-1.18 (-7.54%)

03/02/22 Canaccord
Green Thumb Industries price target lowered to C$43 from C$46 at Canaccord
03/02/22 Stifel
Green Thumb Industries price target lowered to C$73 from C$80 at Stifel
03/02/22 Craig-Hallum
Green Thumb Industries price target lowered to $35 from $40 at Craig-Hallum
IGC India Globalization Capital
/

+

TLRY Tilray
$4.86 /

-0.15 (-3.00%)

04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
ZYNE Zynerba
$1.34 /

-0.045 (-3.26%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
ATAI Atai Life Sciences
$4.40 /

-0.195 (-4.24%)

04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
CMPS Compass Pathways
$9.55 /

-0.655 (-6.42%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$23.38 /

-0.91 (-3.75%)

12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
07/28/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
ZYNE Zynerba
$1.34 /

-0.045 (-3.26%)

TLRY Tilray
$4.86 /

-0.15 (-3.00%)

RLMD Relmada Therapeutics
$23.38 /

-0.91 (-3.75%)

GTBIF Green Thumb Industries
$14.46 /

-1.18 (-7.54%)

CVSI CV Sciences
/

+

CRON Cronos Group
$2.88 /

-0.05 (-1.71%)

CMPS Compass Pathways
$9.55 /

-0.655 (-6.42%)

CLVR Clever Leaves
$1.41 /

-0.055 (-3.75%)

CGC Canopy Growth
$5.10 /

-0.125 (-2.39%)

ATAI Atai Life Sciences
$4.40 /

-0.195 (-4.24%)

ACB Aurora Cannabis
$2.82 /

-0.11 (-3.75%)

  • 09
    Dec
  • 18
    Jun
  • 30
    Apr
TCNNF Trulieve Cannabis
$15.08 /

-0.91 (-5.69%)

TLRY Tilray
$4.86 /

-0.15 (-3.00%)

TCNNF Trulieve Cannabis
$15.08 /

-0.91 (-5.69%)

CLVR Clever Leaves
$1.41 /

-0.055 (-3.75%)

TLRY Tilray
$4.86 /

-0.15 (-3.00%)

CRON Cronos Group
$2.88 /

-0.05 (-1.71%)

CMPS Compass Pathways
$9.55 /

-0.655 (-6.42%)

CLVR Clever Leaves
$1.41 /

-0.055 (-3.75%)

CGC Canopy Growth
$5.10 /

-0.125 (-2.39%)

ATAI Atai Life Sciences
$4.40 /

-0.195 (-4.24%)

ACB Aurora Cannabis
$2.82 /

-0.11 (-3.75%)

On The Fly
Rising High: Exclusive talk with psychedelics organization MAPS PBC » 11:27
04/21/22
04/21
11:27
04/21/22
11:27
ACB

Aurora Cannabis

$3.18 /

-0.045 (-1.40%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$5.75 /

+0.03 (+0.52%)

, CRON

Cronos Group

$3.13 /

-0.08 (-2.49%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.79 /

-0.01 (-0.56%)

, GTBIF

Green Thumb Industries

$16.40 /

-0.25 (-1.50%)

, IGC

India Globalization Capital

/

+

, TLRY

Tilray

$5.38 /

-0.025 (-0.46%)

, TCNNF

Trulieve Cannabis

$17.64 /

-0.572 (-3.14%)

, ZYNE

Zynerba

$1.58 /

-0.035 (-2.17%)

, ATAI

Atai Life Sciences

$4.98 /

-0.105 (-2.06%)

, RLMD

Relmada Therapeutics

$26.47 /

+0.37 (+1.42%)

, CMPS

Compass Pathways

$12.44 /

-0.235 (-1.85%)

, AWKNF

Awakn Life Sciences

$1.21 /

-0.0173 (-1.41%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
$1.58 /

-0.035 (-2.17%)

TLRY Tilray
$5.38 /

-0.025 (-0.46%)

TCNNF Trulieve Cannabis
$17.64 /

-0.572 (-3.14%)

RLMD Relmada Therapeutics
$26.47 /

+0.37 (+1.42%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$16.40 /

-0.25 (-1.50%)

GDNSF Goodness Growth
$1.79 /

-0.01 (-0.56%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.13 /

-0.08 (-2.49%)

CMPS Compass Pathways
$12.44 /

-0.235 (-1.85%)

CGC Canopy Growth
$5.75 /

+0.03 (+0.52%)

ATAI Atai Life Sciences
$4.98 /

-0.105 (-2.06%)

ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
02/03/22 CIBC
Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
11/11/21 Canaccord
Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
CVSI CV Sciences
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CGC Canopy Growth
$5.75 /

+0.03 (+0.52%)

04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
03/01/22 Barclays
Canopy Growth price target lowered to $9 from $14 at Barclays
CRON Cronos Group
$3.13 /

-0.08 (-2.49%)

03/22/22 Barclays
Cronos Group upgraded to Equal Weight from Underweight at Barclays
03/21/22 Stifel
Stifel takes neutral overall view of Cronos' CEO transition
03/07/22 Piper Sandler
Cronos Group price target lowered to $3 from $4 at Piper Sandler
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.79 /

-0.01 (-0.56%)

02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$16.40 /

-0.25 (-1.50%)

03/02/22 Canaccord
Green Thumb Industries price target lowered to C$43 from C$46 at Canaccord
03/02/22 Stifel
Green Thumb Industries price target lowered to C$73 from C$80 at Stifel
03/02/22 Craig-Hallum
Green Thumb Industries price target lowered to $35 from $40 at Craig-Hallum
IGC India Globalization Capital
/

+

TLRY Tilray
$5.38 /

-0.025 (-0.46%)

04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
TCNNF Trulieve Cannabis
$17.64 /

-0.572 (-3.14%)

03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
03/29/22 Cantor Fitzgerald
Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald
ZYNE Zynerba
$1.58 /

-0.035 (-2.17%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
ATAI Atai Life Sciences
$4.98 /

-0.105 (-2.06%)

04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
RLMD Relmada Therapeutics
$26.47 /

+0.37 (+1.42%)

12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
07/28/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
CMPS Compass Pathways
$12.44 /

-0.235 (-1.85%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
AWKNF Awakn Life Sciences
$1.21 /

-0.0173 (-1.41%)

04/01/22 Stifel
Awakn Life Sciences initiated with a Speculative Buy at Stifel
02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
ZYNE Zynerba
$1.58 /

-0.035 (-2.17%)

TLRY Tilray
$5.38 /

-0.025 (-0.46%)

RLMD Relmada Therapeutics
$26.47 /

+0.37 (+1.42%)

GTBIF Green Thumb Industries
$16.40 /

-0.25 (-1.50%)

CVSI CV Sciences
/

+

CRON Cronos Group
$3.13 /

-0.08 (-2.49%)

CMPS Compass Pathways
$12.44 /

-0.235 (-1.85%)

CGC Canopy Growth
$5.75 /

+0.03 (+0.52%)

ATAI Atai Life Sciences
$4.98 /

-0.105 (-2.06%)

ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

  • 09
    Dec
  • 18
    Jun
  • 30
    Apr
ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

TLRY Tilray
$5.38 /

-0.025 (-0.46%)

CTST CannTrust
/

+

AWKNF Awakn Life Sciences
$1.21 /

-0.0173 (-1.41%)

ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

TLRY Tilray
$5.38 /

-0.025 (-0.46%)

CRON Cronos Group
$3.13 /

-0.08 (-2.49%)

CMPS Compass Pathways
$12.44 /

-0.235 (-1.85%)

CGC Canopy Growth
$5.75 /

+0.03 (+0.52%)

ATAI Atai Life Sciences
$4.98 /

-0.105 (-2.06%)

ACB Aurora Cannabis
$3.18 /

-0.045 (-1.40%)

Over a month ago
Hot Stocks
Compass Pathways partners with One Mind for Rising Star Awards » 07:05
04/20/22
04/20
07:05
04/20/22
07:05
CMPS

Compass Pathways

$12.65 /

+0.4 (+3.27%)

COMPASS Pathways…

COMPASS Pathways announced it is partnering with One Mind, a leading mental health research non-profit based in California, to sponsor three "2022 One Mind - COMPASS Rising Stars Awards". The One Mind Rising Star Awards are given each year to promising early career investigators who are pursuing research with the potential to dramatically advance the understanding and treatment of mental illnesses, and to improve patient outcomes. A Request for Applications was issued by One Mind today and up to three winners will be selected by One Mind's Scientific Advisory Board through a competitive process. The winners, to be announced in September 2022, will each receive a $300,000 research grant sponsored by COMPASS over three years. They will also be eligible to participate in select leadership development and entrepreneurship opportunities through the One Mind Rising Star Development Program offered by One Mind.

ShowHide Related Items >><<
CMPS Compass Pathways
$12.65 /

+0.4 (+3.27%)

CMPS Compass Pathways
$12.65 /

+0.4 (+3.27%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
CMPS Compass Pathways
$12.65 /

+0.4 (+3.27%)

  • 30
    Apr
CMPS Compass Pathways
$12.65 /

+0.4 (+3.27%)

CMPS Compass Pathways
$12.65 /

+0.4 (+3.27%)

On The Fly
Here's What You Missed in Cannabis This Week » 10:57
04/14/22
04/14
10:57
04/14/22
10:57
IGC

India Globalization Capital

/

+

, IIPR

Innovative Industrial Properties

$176.49 /

-6.76 (-3.69%)

, TRSSF

TerrAscend

$5.56 /

+0.02 (+0.36%)

, CURLF

Curaleaf

$6.84 /

+0.23 (+3.48%)

, DELCF

Delic Holdings

/

+

, DLTNF

Delta 9 Cannabis

/

+

, FFLWF

Fire & Flower Holdings

$3.78 /

+0.01 (+0.27%)

, ACB

Aurora Cannabis

$3.56 /

-0.13 (-3.52%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$6.82 /

-0.28 (-3.94%)

, CRON

Cronos Group

$3.38 /

-0.105 (-3.01%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.87 /

+0.03 (+1.63%)

, GTBIF

Green Thumb Industries

$16.76 /

+0.36 (+2.20%)

, TLRY

Tilray

$6.12 /

-0.29 (-4.52%)

, TCNNF

Trulieve Cannabis

$18.57 /

-0.206 (-1.10%)

, ZYNE

Zynerba

$1.74 /

-0.04 (-2.25%)

, ATAI

Atai Life Sciences

$5.28 /

+0.09 (+1.73%)

, CMPS

Compass Pathways

$12.78 /

-0.355 (-2.70%)

, RLMD

Relmada Therapeutics

$26.17 /

+0.095 (+0.36%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.74 /

-0.04 (-2.25%)

TRSSF TerrAscend
$5.56 /

+0.02 (+0.36%)

TLRY Tilray
$6.12 /

-0.29 (-4.52%)

TCNNF Trulieve Cannabis
$18.57 /

-0.206 (-1.10%)

RLMD Relmada Therapeutics
$26.17 /

+0.095 (+0.36%)

IIPR Innovative Industrial Properties
$176.49 /

-6.76 (-3.69%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$16.76 /

+0.36 (+2.20%)

GDNSF Goodness Growth
$1.87 /

+0.03 (+1.63%)

DLTNF Delta 9 Cannabis
/

+

DELCF Delic Holdings
/

+

CVSI CV Sciences
/

+

CURLF Curaleaf
$6.84 /

+0.23 (+3.48%)

CTST CannTrust
/

+

CRON Cronos Group
$3.38 /

-0.105 (-3.01%)

CMPS Compass Pathways
$12.78 /

-0.355 (-2.70%)

CGC Canopy Growth
$6.82 /

-0.28 (-3.94%)

ATAI Atai Life Sciences
$5.28 /

+0.09 (+1.73%)

ACB Aurora Cannabis
$3.56 /

-0.13 (-3.52%)

IGC India Globalization Capital
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
IIPR Innovative Industrial Properties
$176.49 /

-6.76 (-3.69%)

01/14/22 Piper Sandler
Innovative Industrial price target lowered to $285 from $290 at Piper Sandler
11/04/21 JMP Securities
Innovative Industrial Properties price target raised to $300 from $260 at JMP Securities
09/08/21 Compass Point
NewLake Capital Partners initiated with a Buy at Compass Point
09/01/21 BTIG
Innovative Industrial Properties price target raised to $290 from $245 at BTIG
TRSSF TerrAscend
$5.56 /

+0.02 (+0.36%)

02/09/22 Clarus
TerrAscend price target lowered to C$14 from C$16.25 at Clarus
12/08/21 Cantor Fitzgerald
TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald
11/17/21 Stifel
TerrAscend price target lowered to C$21 from C$23 at Stifel
11/01/21 Stifel
TerrAscend price target lowered to C$23 from C$25 at Stifel
CURLF Curaleaf
$6.84 /

+0.23 (+3.48%)

03/07/22 Stifel
Curaleaf price target lowered to C$25 from C$31 at Stifel
03/04/22 Alliance Global Partners
Curaleaf price target lowered to C$15 from C$21 at Alliance Global Partners
02/25/22 Benchmark
Curaleaf initiated with a Buy at Benchmark
02/07/22 Alliance Global Partners
Cannabis operators in PA could see near-term impact to sales, says AGP
DELCF Delic Holdings
/

+

DLTNF Delta 9 Cannabis
/

+

FFLWF Fire & Flower Holdings
$3.78 /

+0.01 (+0.27%)

12/15/21 Stifel
Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel
11/23/21 Cantor Fitzgerald
Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald
11/22/21 Cantor Fitzgerald
Fire & Flower initiated with an Overweight at Cantor Fitzgerald
ACB Aurora Cannabis
$3.56 /

-0.13 (-3.52%)

02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
02/03/22 CIBC
Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC
11/11/21 Canaccord
Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord
CVSI CV Sciences
/

+

CTST CannTrust
/

+

CGC Canopy Growth
$6.82 /

-0.28 (-3.94%)

04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
03/01/22 Barclays
Canopy Growth price target lowered to $9 from $14 at Barclays
CRON Cronos Group
$3.38 /

-0.105 (-3.01%)

03/22/22 Barclays
Cronos Group upgraded to Equal Weight from Underweight at Barclays
03/21/22 Stifel
Stifel takes neutral overall view of Cronos' CEO transition
03/07/22 Piper Sandler
Cronos Group price target lowered to $3 from $4 at Piper Sandler
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.87 /

+0.03 (+1.63%)

02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$16.76 /

+0.36 (+2.20%)

03/02/22 Canaccord
Green Thumb Industries price target lowered to C$43 from C$46 at Canaccord
03/02/22 Stifel
Green Thumb Industries price target lowered to C$73 from C$80 at Stifel
03/02/22 Craig-Hallum
Green Thumb Industries price target lowered to $35 from $40 at Craig-Hallum
TLRY Tilray
$6.12 /

-0.29 (-4.52%)

04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
03/17/22 Piper Sandler
Tilray price target lowered to $6 from $8 at Piper Sandler
TCNNF Trulieve Cannabis
$18.57 /

-0.206 (-1.10%)

03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
03/29/22 Cantor Fitzgerald
Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald
ZYNE Zynerba
$1.74 /

-0.04 (-2.25%)

05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
ATAI Atai Life Sciences
$5.28 /

+0.09 (+1.73%)

04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
CMPS Compass Pathways
$12.78 /

-0.355 (-2.70%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$26.17 /

+0.095 (+0.36%)

12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
07/28/21 Truist
Relmada Therapeutics price target raised to $90 from $75 at Truist
ZYNE Zynerba
$1.74 /

-0.04 (-2.25%)

TLRY Tilray
$6.12 /

-0.29 (-4.52%)

RLMD Relmada Therapeutics
$26.17 /

+0.095 (+0.36%)

IIPR Innovative Industrial Properties
$176.49 /

-6.76 (-3.69%)

GTBIF Green Thumb Industries
$16.76 /

+0.36 (+2.20%)

DLTNF Delta 9 Cannabis
/

+

CVSI CV Sciences
/

+

CURLF Curaleaf
$6.84 /

+0.23 (+3.48%)

CRON Cronos Group
$3.38 /

-0.105 (-3.01%)

CMPS Compass Pathways
$12.78 /

-0.355 (-2.70%)

CGC Canopy Growth
$6.82 /

-0.28 (-3.94%)

ATAI Atai Life Sciences
$5.28 /

+0.09 (+1.73%)

ACB Aurora Cannabis
$3.56 /

-0.13 (-3.52%)

  • 01
    Apr
  • 09
    Dec
  • 18
    Jun
  • 30
    Apr
IIPR Innovative Industrial Properties
$176.49 /

-6.76 (-3.69%)

IGC India Globalization Capital
/

+

TRSSF TerrAscend
$5.56 /

+0.02 (+0.36%)

TLRY Tilray
$6.12 /

-0.29 (-4.52%)

IGC India Globalization Capital
/

+

FFLWF Fire & Flower Holdings
$3.78 /

+0.01 (+0.27%)

CURLF Curaleaf
$6.84 /

+0.23 (+3.48%)

CTST CannTrust
/

+

TLRY Tilray
$6.12 /

-0.29 (-4.52%)

CRON Cronos Group
$3.38 /

-0.105 (-3.01%)

CMPS Compass Pathways
$12.78 /

-0.355 (-2.70%)

CGC Canopy Growth
$6.82 /

-0.28 (-3.94%)

ATAI Atai Life Sciences
$5.28 /

+0.09 (+1.73%)

ACB Aurora Cannabis
$3.56 /

-0.13 (-3.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.